A Study of Coformulated Favezelimab/?Pembrolizumab (MK-4280A) Versus Physician`s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Complete Title: A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Trial Phase: III

Investigator: Ryan Lynch

The purpose of this study is to compare efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) with physician`s choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory, relapsed or refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of coformulated favezelimab/pembrolizumab. The primary study hypotheses are that coformulated favezelimab/pembrolizumab is superior to physician`s choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).

Keywords:

Lymphoma, Hodgkin

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.